GlassScriptPhysician profile
Robin Niederwerfer
NPI 1871781450
$5,533.38
in general payments reported to CMS, 2019-2025
23 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $882 · 2023: $1,119 · 2024: $1,432 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.10 | 2021-2025 | |
| Janssen Biotech, INC. | $857.63 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $414.00 | 2021-2024 | Linzess |
| Ardelyx, INC. | $412.54 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $307.20 | 2021-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.41 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $270.49 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $220.06 | 2024-2025 | Omvoh |
| Celgene Corporation | $195.99 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $183.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $146.00 | 2022-2024 | Injectafer |
| Braintree Laboratories, INC. | $126.04 | 2021-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $125.06 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $78.96 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $67.79 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51.42 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $43.17 | 2021 | |
| Celltrion USA INC. | $33.71 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $24.81 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.95 | 2023 | Ocaliva |
| Amgen INC. | $18.58 | 2021 | |
| Medtronic, INC. | $15.73 | 2024 | Interstim |
| Ferring Pharmaceuticals INC. | $14.86 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Niederwerfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.